Novel hydroxyapatite biomaterial covalently linked to raloxifene

L. Memè, A. Santarelli, G. Marzo, M. Emanuelli, P. F. Nocini, D. Bertossi, A. Putignano, M. Dioguardi, L. Lo Muzio, F. Bambini

Research output: Contribution to journalArticlepeer-review


Since raloxifene, a drug used in osteoporosis therapy, inhibits osteoclast, but not osteoblast functions, it has been suggested to improve recovery during implant surgery. The present paper describes an effective method to link raloxifene, through a covalent bond, to a nano-Hydroxyapatite-based biomaterial by interfacing with (3-aminopropylKIYiethoxysilane as assessed by Infra Red-Fourier Transformed (IR-FT) spectroscopy and Scanning Electron Microscope (SEM). To evaluate the safety of this modified new material, the vitality of osteoblast-like celis cultured with the new biomaterial was then investigated. Raloxifene-conjugated HA- biomaterial has been shown to be a safe material easy to obtain which could be an interesting starting point for the use of a new functional biomaterial suitable in bone regeneration procedures.

Original languageEnglish
Pages (from-to)437-444
Number of pages8
JournalInternational Journal of Immunopathology and Pharmacology
Issue number3
Publication statusPublished - Jul 1 2014


  • (3-aminopropyl)-triethoxysilane
  • Covalent bond
  • Nanohydroxiapatite
  • Osteoblast
  • Raloxifene

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Novel hydroxyapatite biomaterial covalently linked to raloxifene'. Together they form a unique fingerprint.

Cite this